Presentations, Podcasts, & Articles
Year End Board meeting, December 10, 2024
Our board members and investors called in from Mauritius, Kenya, Rwanda, Benin, Haiti and throughout the USA, Asia, and Europe.
The board room in our Waltham, Massachusetts headquarters was filled with C-level officers, our patent attorney, advisers to the chairman, our corporate attorneys, and heads of vaccines, quality, and preclinical experiments.
We had a long discussion on upcoming regulatory changes, sources and uses of cash including a new $14 mn grant to develop our avian flu vaccine to fight the next pandemic, and our TB drug trial now underway in Africa.
Berlin, October 14, 2024 ceremonial signing of the unprecedented 2 million euro grant to a private African enterprise from the European Investment Bank to Akagera Medicines, Africa. From left to right: Dr. Daryl Drummond; EIB Relationship Manager and Head of Unit, Antonin Calzarossa; Michael Fairbanks, Ambassador Albrecht Conze; former Cabinet Member of Sweden and Vice President of the EIB, Thomas Östros; Chief Investment Officer of the Rwanda Social Security Board, Philippe Watrin; Lead Life Science Specialist, Anna Lynch; and EIB Director of Innovation, Felicitas Riedl.
October 13-15, 2024 Berlin, Germany
The World Health Summit, with the Federal Chancellor of Germany, Olaf Scholz, Bill Gates, and the heads of the Global Fund, GAVI, and the WHO brought 13,000 stakeholders from 100 nations in the fields of politics, science, the private sector, and civil society to set the agenda for a healthier future.
Akagera Medicines’ Michael Fairbanks, Dr. Daryl Drummond, Philippe Watrin & Ambassador Albrecht Conze attended a Press Conference with the European Investment Bank and their first meeting with the €750 million Human Development Accelerator (HDX).
October 8-10, 2024: Rio de janeiro, brazil
For the first time in more than a century, new TB vaccines are within reach.
The theme for the 7th Global Forum on TB Vaccines – Driving innovation from discovery to access – speaks to the pivotal moment we are facing in TB vaccine development.
Dr. Ross Fulton is a keynote speaker.
September 17-18, 2024: Kigali, Rwanda
East Africa Pharma and Biotech Conference is hosted by the Government of Rwanda represented by the Rwanda Biomedical Centre (RBC) and the Africa Centres for Disease Control and Prevention (Africa CDC) with support from German Cooperation.
Akagera Med’s Country Manager, Moses Asiimwe will be a panelist.
September 9-11, 2024: Heidelberg, Germany
The Symposium is intended to bring together phospholipid scientists from all over the world, offering the opportunity to initiate exciting discussions and long-term collaborations.
Dr. Daryl Drummond keynote on Targeting LNPs for highly efficacious therapeutics and vaccines against difficult-to-treat infectious diseases.
September 1-5, 2024: Rome, Italy
The EFMC is the main organisation for the European Medicinal Chemistry and Chemical Biology community, with 30 member societies and about 9.000 members. Its biennial EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery and it traditionally attracts around 1.000 participants both from industry and academia.
Dr. Daryl Drummond presenting on day 4.
August 20-22, 2024: Boston Ma.
Join Akagera Medicines co-founder, Dr. Daryl Drummond, PhD. at the 3rd annual Next Generation Lipid-Based Nanoparticles Delivery Summit.
June 28, 2024: KigaLi Rwanda
Understanding Rwanda’s Biotech Strategy
By: Akagera Medicines co-founders, Michael Fairbanks & Dr. Daryl Drummond, PhD.
June 20, 2024: quai d’Orsay Paris France
President Kagame arrives in France to deliver remarks at the opening session of the Global Forum for Vaccine Sovereignty and Innovation.
June 11, 2024: Gates Foundation, Redmond wa.
Ross Fulton, PhD. presents TB Vaccine data to closed door session with the world’s leading TB scientists.
may 7-9, 2024: Boston, Ma.
Akagera Medicines co-founder Dr. Daryl Drummond, PhD. at Next Generation RNA Therapeutics Summit.
April 16, 2024: Waltham, Ma.
Alex Ntale, CEO of the Rwandan ICT Chamber of Commerce visits Akagera Medicines in Waltham, Massachusetts and is among the first people to hold Akagera Medicines’ TB therapeutic.
Phase I trials begin Q4 in Africa.
April 13, 2024: Harvard University
AFRICA DEVELOPMENT CONFERENCE - Strengthening Africa's Healthcare Systems at Harvard Law School: Michael Fairbanks shares the stage with Dr. Yelli Aluko of Ernst and Young, Dr. Awa Marie Coll-Seck, former Minister of Health of Senegal; Dr Nnneka Mobisson, founder of MDOC in Nigeria; and Dr. Amadou Sall of the Pasteur Institute in Senegal.
PM: March 26, 2024: Waltham, Ma.
Francis Gatare, Chief Executive of the Rwanda Development Board and member of President Kagame's cabinet, visits Akagera Medicines headquarters outside Boston. Immunologist Dr. Ross Fulton briefs Francis on schedule for vaccine trials.
AM: March 26, 2024: Waltham, Ma.
Science advisors from Harvard, Duke, UNC, Oxford, and the Gates Foundation look at the latest TB therapeutic data and the application for Akagera Medicines trials in Africa in summer of 2024.
March 12, 2024: LUXEMBOURG
Akagera Medicines’ Dr. Daryl Drummond and Ambassador Conze (on right) make final presentation to senior science and finance leadership of the European Investment Bank in Luxembourg.
February 13, 2024: medpage today
Akagera Medicines’ founders, Dr. Daryl Drummond and Dr. Dmitri Kirpotin learn that FDA approved their first line treatment for Pancreatic Cancer based on superior delivery system.
February 2-3, 2024: the long form, Washington, DC
Akagera Medicines co-founder Michael C. Fairbanks attends Rwanda Day,
Washington DC
December 19, 2023: Shareholder briefing
Global healthcare equity
Here is a recent non-confidential briefing. (Confidential slides are removed.)
July 14, 2023: The new times
Eradicating tuberculosis: What has to be done and is there a role for Rwanda?
By: Michael C. Fairbanks & Daryl Drummond
June 14, 2023: Kigali
The first East Africa Pharma and Biotech Conference opened in Kigali, with Rwanda getting new investment opportunities in the pharmaceuticals and vaccines manufacturing industry.
June 29, 2023: Sagamore Institute at Harvard
Michael C. Fairbanks shares lessons learned from Rwanda’s economic revival.
November 9, 2022: Ipsen Press Release, Paris France
Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma.
october 27, 2022: harvard University
The Institute of Global Health Equity Research at the University of Global Health Equity (UGHE), Rwanda’s newest medical school founded by Dr. Paul Farmer and Dr. Agnes Binagwaho, was launched at Harvard University and in Kigali, Rwanda. Speakers included Dr. Jim Yong Kim, former President of the World Bank; Dr. Esther Duflo, MIT professor and Nobel Laureate in Economics; Dr. Joia Mukherjee, Chief Medical Officer of Partners in Health; Dr. Claire Wagner, Chief Strategist of the Gates Research Institution; and Michael Fairbanks, Executive Chairman and Founder of Akagera Medicines (on right); and the leaders of Harvard Medical School, the Massachusetts General and Brigham Hospital, and the Rwandan embassy in Washington.
October 27, 2022: World Health Organization
Global tuberculosis report 2022
September 15, 2022: New England Journal of Medicines
COVID-19 VACCINES - IMMUNITY, VARIANTS, BOOSTERS
By Dan H. Barouch, M.D., PH.D.
september 13, 2022: Project syndicate
Investing in Africa’s Health
By Donald P. Kaberuka
July 14, 2022: The New Times
The Biotech Revolution Has Begun in Rwanda
By: Michael C. Fairbanks & Daryl Drummond
february 14, 2020: National Leadership Conference
Rwanda: President Kagame (front row center), Dr. Paul Farmer, Dr. Donald Kaberuka and Michael Fairbanks meet at National Leadership Conference and discuss Akagera Medicines board membership.
July 1, 2020: The Journal of infectious diseases
By: Robert W. Eisinger, Alan C. Embry, Sarah W. Read, and Anthony S. Fauci
March 20, 2019: Building a tuberculosis-free world: The Lancet Commission
on tuberculosis
Tuberculosis can be treated, prevented, and cured. Rapid, sustained declines in tuberculosis deaths in many countries during the past 50 years provide compelling evidence that ending the pandemic is feasible. Yet this disease—which has plagued humanity since before recorded history and has killed hundreds of millions of people over the past two centuries—remains a relentless scourge.
february 23, 2017: Project Syndicate
Why TB Persists
By: Michael C. Fairbanks
February 1,2017: project syndicate
The Heart of Africa’s New Medical School
By: Michael C. Fairbanks
September, 2013: Free Market series
Solutions to Poverty
with Michael C. Fairbanks